CD8A and cancer: Exhausted T cells can be reinvigorated by αPD-1 blockade, leading to improved T cell functionality and antitumor response in a considerable proportion of cancer patients.27 Given the metabolic advantages conferred by PGC-1α expression, we then tested the therapeutic benefit of combining ACT of PGC-1α-engineered CD8 T cells with PD-1 blockade.